RCKT
Price
$21.36
Change
-$0.00 (-0.00%)
Updated
Sep 19 closing price
47 days until earnings call
XENE
Price
$40.79
Change
-$0.00 (-0.00%)
Updated
Sep 19 closing price
46 days until earnings call
Ad is loading...

RCKT vs XENE

Header iconRCKT vs XENE Comparison
Open Charts RCKT vs XENEBanner chart's image
Rocket Pharmaceuticals
Price$21.36
Change-$0.00 (-0.00%)
Volume$761.07K
CapitalizationN/A
Xenon Pharmaceuticals
Price$40.79
Change-$0.00 (-0.00%)
Volume$220.49K
CapitalizationN/A
View a ticker or compare two or three
RCKT vs XENE Comparison Chart
Loading...
RCKT
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
RCKT vs. XENE commentary
Sep 21, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RCKT is a Hold and XENE is a Buy.

COMPARISON
Comparison
Sep 21, 2024
Stock price -- (RCKT: $20.84 vs. XENE: $40.09)
Brand notoriety: RCKT and XENE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RCKT: 151% vs. XENE: 107%
Market capitalization -- RCKT: $1.83B vs. XENE: $3.09B
RCKT [@Biotechnology] is valued at $1.83B. XENE’s [@Biotechnology] market capitalization is $3.09B. The market cap for tickers in the [@Biotechnology] industry ranges from $595.57B to $0. The average market capitalization across the [@Biotechnology] industry is $2.99B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RCKT’s FA Score shows that 0 FA rating(s) are green whileXENE’s FA Score has 2 green FA rating(s).

  • RCKT’s FA Score: 0 green, 5 red.
  • XENE’s FA Score: 2 green, 3 red.
According to our system of comparison, XENE is a better buy in the long-term than RCKT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RCKT’s TA Score shows that 5 TA indicator(s) are bullish while XENE’s TA Score has 7 bullish TA indicator(s).

  • RCKT’s TA Score: 5 bullish, 4 bearish.
  • XENE’s TA Score: 7 bullish, 2 bearish.
According to our system of comparison, XENE is a better buy in the short-term than RCKT.

Price Growth

RCKT (@Biotechnology) experienced а +9.51% price change this week, while XENE (@Biotechnology) price change was +3.73% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.40%. For the same industry, the average monthly price growth was +1.46%, and the average quarterly price growth was -0.90%.

Reported Earning Dates

RCKT is expected to report earnings on Nov 06, 2024.

XENE is expected to report earnings on Nov 05, 2024.

Industries' Descriptions

@Biotechnology (+0.40% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XENE($3.09B) has a higher market cap than RCKT($1.84B). XENE YTD gains are higher at: -12.961 vs. RCKT (-30.464). XENE (-233.68M) and RCKT (-243.06M) have comparable annual earnings (EBITDA) . XENE has more cash in the bank: 722M vs. RCKT (279M). XENE has less debt than RCKT: XENE (10M) vs RCKT (25.8M). RCKT (0) and XENE (0) have equivalent revenues.
RCKTXENERCKT / XENE
Capitalization1.84B3.09B59%
EBITDA-243.06M-233.68M104%
Gain YTD-30.464-12.961235%
P/E RatioN/AN/A-
Revenue00-
Total Cash279M722M39%
Total Debt25.8M10M258%
FUNDAMENTALS RATINGS
RCKT vs XENE: Fundamental Ratings
RCKT
XENE
OUTLOOK RATING
1..100
7317
VALUATION
overvalued / fair valued / undervalued
1..100
53
Fair valued
97
Overvalued
PROFIT vs RISK RATING
1..100
7911
SMR RATING
1..100
9794
PRICE GROWTH RATING
1..100
5853
P/E GROWTH RATING
1..100
1007
SEASONALITY SCORE
1..100
4250

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RCKT's Valuation (53) in the Biotechnology industry is somewhat better than the same rating for XENE (97). This means that RCKT’s stock grew somewhat faster than XENE’s over the last 12 months.

XENE's Profit vs Risk Rating (11) in the Biotechnology industry is significantly better than the same rating for RCKT (79). This means that XENE’s stock grew significantly faster than RCKT’s over the last 12 months.

XENE's SMR Rating (94) in the Biotechnology industry is in the same range as RCKT (97). This means that XENE’s stock grew similarly to RCKT’s over the last 12 months.

XENE's Price Growth Rating (53) in the Biotechnology industry is in the same range as RCKT (58). This means that XENE’s stock grew similarly to RCKT’s over the last 12 months.

XENE's P/E Growth Rating (7) in the Biotechnology industry is significantly better than the same rating for RCKT (100). This means that XENE’s stock grew significantly faster than RCKT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RCKTXENE
RSI
ODDS (%)
Bullish Trend 4 days ago
67%
Bullish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
83%
MACD
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 22 days ago
84%
Bullish Trend 8 days ago
80%
Declines
ODDS (%)
Bearish Trend 9 days ago
82%
Bearish Trend 15 days ago
76%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
87%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
88%
View a ticker or compare two or three
Ad is loading...
RCKT
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HRMVX27.67-0.02
-0.07%
Harbor Mid Cap Value Admin
ARTTX22.73-0.02
-0.09%
Artisan Focus Fund Investor
TILCX25.43-0.05
-0.20%
T. Rowe Price Lrg Cp Va I
RIDHX25.53-0.06
-0.23%
American Funds Income Fund of Amer R5E
RYPMX42.77-0.57
-1.32%
Rydex Precious Metals Inv

RCKT and

Correlation & Price change

A.I.dvisor indicates that over the last year, RCKT has been loosely correlated with RYTM. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if RCKT jumps, then RYTM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RCKT
1D Price
Change %
RCKT100%
-4.40%
RYTM - RCKT
53%
Loosely correlated
+0.88%
FOLD - RCKT
53%
Loosely correlated
-2.59%
RXRX - RCKT
53%
Loosely correlated
+2.22%
AXON - RCKT
52%
Loosely correlated
+0.12%
BEAM - RCKT
51%
Loosely correlated
-0.27%
More

XENE and

Correlation & Price change

A.I.dvisor indicates that over the last year, XENE has been loosely correlated with AXSM. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if XENE jumps, then AXSM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XENE
1D Price
Change %
XENE100%
N/A
AXSM - XENE
42%
Loosely correlated
+0.66%
PLRX - XENE
40%
Loosely correlated
-0.79%
RCKT - XENE
40%
Loosely correlated
-4.40%
ALT - XENE
36%
Loosely correlated
-1.85%
TNYA - XENE
36%
Loosely correlated
-2.42%
More